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Abstract
Pseudomyxoma peritonei (PMP) is a rare condition resulting from mucin-producing tumors that have disseminated into
intraperitoneal implants and mucinous ascites. The extra-abdominal spread of PMP is exceptionally rare, with few reported
cases in the medical literature. Pseudomyxoma pleurii is an infrequently encountered clinical syndrome characterized by
transdiaphragmatic pleural extension and spread of PMP. The disease is highly fatal. We hereby report a case of 58 years old
woman who presented with an abdominal distension and shortness of breath of 2 months duration. Histopathology confirmed
the diagnosis of large mucin-producing rectosigmoid adenomatous polypoid lesion with malignant transformation and PMP
that had spread to the right pleural space. PMP from colon tumor is uncommon and its transdiaphragmatic pleural extension
is very unusual complicated by management challenge and high mortality rate.
INTRODUCTION
First case of Pseudomyxoma peritonei (PMP) was described by
Rokitansky in 1842 [1]. In 1884, Werth found its associated with
the ovarian cancer. In 1901, Franckel et al. found its association
with appendiceal cystic tumors [2]. PMP is a rare clinical condi-
tion resulting from accumulation of copious mucinous material
from mucin-producing tumors that disseminate into abdomen,
peritoneal and pelvic cavities as ascites and implants. It is
characterized by chronic, relapsing, disease [3]. The presence of
neoplastic and inflammatory cells in the mucinous secretions
distinguishes this condition from simple ascites. Patients who
have PMP and have disseminated peritoneal adenomucinosis
have more favorable prognosis than patients who have periton-
eal mucinous carcinomatosis [4, 5]. This tumor is mainly super-
ficially invasive but still is a fatal disease. Because of this
unusual pattern of dissemination, it draws significant attention
and interest from the surgical oncologists as it pertains to pur-
sue aggressive loco-regional therapy in order to improve sur-
vival and possible cure. Pseudomyxoma pleurii is a condition
where the pleural cavity is filled with mucinous material. It is
caused by the transdiaphragmatic spread of PMP from abdom-
inal origin [6]. Massive pleural disease is a life threatening con-
dition that impairs cardiopulmonary functions. PMP mostly
arises from appendiceal adenomas or mucinous cyst, adenocar-
cinoma or ruptured primary ovarian cancer, but can also arise
from an indeterminate site [7, 8].
CASE PRESENTATION
A 58-year-old lady was admitted to our hospital with the com-
plaints of shortness of breath, abdominal distension and loss of
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appetite for 2-month duration. She was diagnosed with liver
cirrhosis in another hospital 2 weeks prior to this presentation.
She was referred to us for the management of large ascites,
which was thought to be from decompensated chronic liver
disease. She was treated for toxic goiter some years back with
radioactive iodine therapy and was lost to follow-up.
She had a history of drinking a bottle of wine and spirits dai-
ly for 30 years. She denied any smoking history. On physical
examination she was alert and oriented, afebrile, had pallor but
there was no evidence of jaundice or edema. Systemic examin-
ation revealed tachypnea (32b/min), tachycardia 128/b/min,
desaturating on room air (SpO2 88%). Chest percussion revealed
stony dullness on the right side. Cardiovascular examination
was normal apart from tachycardia. Abdomen was grossly dis-
tended with mild tenderness and shifting dullness but no orga-
nomegaly or masses. Rectal examination was normal.
Complete blood count showed iron deficient anemia with
low hemoglobin of 8.7 g/dl and mild neutrophilia and monocy-
tosis. Liver function tests were normal. Renal function tests
were normal. Viral hepatitis B and C, HIV I/II tests were all
negative. Erythrocyte sedimentation rate (ESR) was high
(70mm/h). C-reactive protein (CRP) was slightly high (34.4mg/l).
Serum alpha fetoprotein (AFP) was normal (4.38 ng/ml) and ser-
um CA-125, CA 19-9, and carcinoembryonic antigen (CEA) and
lactate dehydrogenase (LDH) were all elevated (166.70U/ml,
354.40U/ml, 300.20 ng/ml, 329.30U/l, respectively). Serum thy-
roid stimulating hormone (TSH) was high (9.77 uIU/ml), T3 and
T4 were critically low (0.686 and 5.07 pmol/l, respectively). Chest
X-ray revealed large right pleural effusion with possible under-
lying collapse/consolidation (Fig. 1). Computed tomography scan
of the abdomen revealed large ascites, scalloping of the liver
margins with multiple subcapular lesions (largest measuring
12.8 × 6.4 cm2), peritoneal deposits and large mixed echogenicity
solid lesion seen all over abdomen and pelvis, involving omen-
tum and mesentery extending into poach of Douglas. Gall blad-
der, urinary bladder, uterus and ovaries were not seen
separately from this lesion (Fig. 2). This was interpreted to be
large intraperitoneal tumor deposit. Visualized bowel loops
appeared normal. Common bile duct (CBD), spleen and both kid-
neys were normal. Intraperitoneal, omental and mesentery fluid
loculations were noted. The findings were suggestive of PMP.
Ascites fluid tap revealed neutrophils 2600/μl, was exudative but
negative for adenosine deaminase (ADA), Zeil Nelson stain,
Indian ink, gram stain and culture. Pleural fluid was exudative
and had cell count 1000/μl and the rest of tests were negative in
the ascites fluid sampling. Cytology smear showed predomin-
antly 80% lymphocytes and 20% polymorphs with proteinaceous
Figure 1: X-ray chest AP view showing large right pleural effusion with loss of
right costo-phrenic and cardio-phrenic angle.
Figure 2: CT scan of the abdomen revealed multiple subcapsular lesion, peritoneal deposit and large ascites (shown via arrow).
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background showing few RBCs. Colonoscopy revealed a very
large polypoid but soft lesion with features of a villous adenoma
in the rectosigmoid (20–30 cm from anal verge) with possible
malignant transformation (Fig. 3). Colonoscopic biopsies
revealed villous adenoma with moderate dysplasia and focal
invasion (Fig. 4A and B). In view of multiple tumor metastasis
and PMP, features were consistent with malignant transform-
ation. Biopsies from omental masses revealed extracellular
mucin pools with floating clusters.
Computerized tomography-positronic emissions tomog-
raphy (CT-PET scan) of the head, chest and abdomen was
done which showed uptake in peritoneal cavity, sub-
diaphragmatic, inferior surface of the liver, omentum, pelvis
with mucinous and in the sigmoid colon. These findings con-
firmed the diagnosis of PMP and sigmoid primary neoplastic
pathology (Fig. 5). Also seen was uptake along bowel loops and
right pleura.
DISCUSSION
PMP is uncommon clinical condition caused by dissemination
in the abdominal cavity of mucinous adenocarcinoma cells
from mucin-producing tumors that results in mucinous or
gelatinous ascites [9]. It rarely spreads via the lymphatic sys-
tem or through the blood stream. PMP is characterized by hav-
ing mucin and scattered cancer cells in the abdominal cavity
(also referred as gelatinous collections or jelly belly) with
mucinous implants on the omental and the peritoneal surfaces
[10]. In the absence of treatment, mucin will ultimately build
up and will compress the vital structures as the stomach, kid-
neys, colon, liver, pancreas and spleen. This is also known as
local and regional distribution or loco-regional progression [11],
which as a result of raised intra-abdominal pressure and
abdominal compartment syndrome can results in impairment
of intestinal function and lead to malnutrition, fistula forma-
tion and infections [12]. This leads to significantly increased
mortality and morbidity. PMP in the old literature was said to
occur from a variety of primary tumors but mainly from appen-
dicular tumors [8, 11, 13]. Recently, PMP from colorectal tumors
have been reported, which is very rare [14]. Pseudomyxoma
pleurii is an even uncommon pathological form which is char-
acterized by the presence of malignant mucinous implants due
to transdiaphragmatic spread of the PMP [6]. In the index
patient the primary tumor was an adenocarcinoma in the sig-
moid colon causing PMP with extension to the right pleura caus-
ing pseudomyxoma pleurii, making it a very rare presentation
Figure 3: Colonoscopy revealed large polypoid but soft lesions with features of villous adenoma in the rectosigmoid colon (shown via arrow).
Figure 4: (A) Low power and (B) high power images of colonic biopsy showing villous adenoma with moderate dysplasia and focal invasion.
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among only few cases reported in the literature. This condition
is often misdiagnosed in the early part of the disease process as
decompensated chronic liver disease with massive ascites due
to patient having similar non-specific symptoms in the early
stages of the disease. This patient had presented very late with
extensive disease dissemination. As it was also observed in this
patient, routine laboratory studies are seldom helpful in making
the diagnosis. Radiology imaging with computed tomography
helps in suggesting the diagnosis but histopathology is the gold
standard and provides the confirmatory diagnosis [3, 4]. Patients
with PMP with adenomucinosis have much favorable prognosis
when compared to patients with peritoneal mucinous carcin-
omatosis [2, 5]. CT-PET scan is useful to detect extent of the dis-
ease and potential for treatment [15]. Even with the better
understanding and recent advances in the management of this
disease, PMP creates a diagnostic challenge in the early stage of
the disease. PMP patients who have elevated pre-operative
tumor markers such as CEA cancer antigen 125 (CA 125) and
carbohydrate antigen 19-9 (CA 19-9) are at increased risk of
developing recurrent disease despite aggressive treatment [3].
PMP patients who have normal tumor marker levels have a bet-
ter overall survival overall [16, 17]. Our patient has presented
late in the course of the disease, making it challenging. The
main therapeutic goal is prevention of local and regional recur-
rence. Surgery and complete cytoreduction treatment combin-
ation followed by intraperitoneal chemotherapy, rather than
intravenous chemotherapy have been suggested as standard
treatment option. Cytoreductive (debulking) surgery and hyper-
thermic intraperitoneal chemotherapy (HIPEC) has been also
suggested as an effective treatment options for treatment of
patients who have peritoneal surface metastatic cancers such as
stage IV colon cancer and PMP. HIPEC therapy produces hyper-
thermia which improves the penetration of tumor by the che-
motherapeutic agents. Systemic effects are much less due to the
peritoneum–blood barrier [6]. This technique is a two-step pro-
cess: first phase entails surgically removing any visible tumor or
cancer, and in phase 2 delivering heated chemotherapy drugs
into the affected area [18]. Systemic chemotherapy is primarily
recommended for patients with extensive peritoneal disease and
high-grade cystadenocarcinoma [19].
Prognosis in patients with PMP is closely related to the tumor
burden, pre-operative tumor volume success of tumor resection
by cytoreductive surgery and pathological classification [20]. Our
patient was started on combination systemic chemotherapy
with FOLFOX (folinic acid (leucovorin), 5-fluorouracil (5FU) and
oxaliplatin) for 4 months before she underwent HIPEC surgery
when CEA was <50ng/ml.
CONCLUSION
PMP is a rare and frequently misdiagnosed condition.
Pseudomyxoma pleurii (involvement of the pleural cavity) via
transdiaphragmatic spread of PMP is very rare with an unfavor-
able prognosis. Local and or systemic chemotherapy with
extensive cytoreduction procedures and treatment should be
considered. In this patient systemic chemotherapy was given
as palliative therapy. Clinical suspicion should be high for early
diagnosis of this rare entity.
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Figure 5: PET-CT scan showing uptake in peritoneal, sub-diaphragmatic, inferior surface of liver, omental area and pelvic area.
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